Evercore ISI Group Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $55

Benzinga Newsdesk www.benzinga.com Positive 93.3%

Neg 0% Neu 0% Pos 93.3%

Evercore ISI Group analyst Cory Kasimov maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $45 to $55.